Neonatal Fc Receptor-Targeted Therapies in Neurology.

Neurotherapeutics · 2022 · PMC9294083 · PMID 34997443

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Treatment with Rozanolixizumab did not reach statistical significance for the change to baseline QMG-score as primary endpoint.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.